DeVita Hellman and Rosenberg s Cancer Principles and Practice of Oncology 12th Edition by Vincent T Devita Jr, Theodore S Lawrence, Steven A Rosenberg ISBN 9781975184681 1975184688

DeVita Hellman and Rosenberg s Cancer Principles and Practice of Oncology 12th Edition by Vincent T Devita Jr, Theodore S Lawrence, Steven A Rosenberg – Ebook PDF Instant Download/Delivery: 9781975184681 ,1975184688
Full download DeVita Hellman and Rosenberg s Cancer Principles and Practice of Oncology 12th Edition after payment

Product details:

ISBN 10: 1975184688
ISBN 13: 9781975184681
Author: Vincent T Devita Jr, Theodore S Lawrence, Steven A Rosenberg

DeVita Hellman and Rosenberg s Cancer Principles and Practice of Oncology 12th Edition Table of contents:

PART I Etiology and Prevention of Cancer

1. Global Cancer Incidence and Mortality

INTRODUCTION

DATA SOURCES

Cancer Incidence

Cancer Mortality

Global Estimates of Cancer Risk and Burden

MEASURES OF BURDEN

Number of New Cancer Cases and Deaths

Prevalent Cases

MEASURES OF RISK

Incidence and Mortality Rates

Cumulative Risk

Survival

DEMOGRAPHIC FACTORS THAT AFFECT CANCER RISK

Age

Sex

Socioeconomic Status

Race and Ethnicity

Place of Residence

GLOBAL PATTERNS OF CANCER RISK AND BURDEN

Geographic Variation

Socioeconomic Variation

Temporal Variation

PATTERNS OF MOST COMMON CANCERS

Female Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Stomach Cancer

Liver Cancer

Esophageal Cancer

Cervical Cancer

Thyroid Cancer

Bladder Cancer

ISSUES IN INTERPRETING TEMPORAL TRENDS

FUTURE BURDEN OF CANCER

CONCLUSION

2. Tobacco Use and the Cancer Patient

INTRODUCTION

TOBACCO USE EPIDEMIOLOGY, ADDICTION, AND TOBACCO PRODUCT EVOLUTION

Epidemiology of Addiction

ELECTRONIC NICOTINE DELIVERY SYSTEMS, OR ELECTRONIC CIGARETTES

DEFINING TOBACCO USE BY THE CANCER PATIENT

EPIDEMIOLOGY OF TOBACCO USE AND CESSATION BY CANCER PATIENTS

SMOKING CESSATION IN THE CONTEXT OF LUNG CANCER SCREENING

THE CLINICAL EFFECTS OF SMOKING AND CESSATION ON CANCER TREATMENT OUTCOMES

The Clinical Effects of Smoking on Cancer Outcomes

The Effects of Smoking on Cancer Costs

The Effects of Smoking Cessation After Diagnosis on Cancer Treatment Outcomes

Smoking, Targeted Therapeutics, and Immunotherapy

Summarizing the Clinical Effects of Smoking and Cessation in Cancer Patients

ADDRESSING TOBACCO USE BY THE CANCER PATIENT

Smoking Cessation Guidelines

Implementing Smoking Cessation into Clinical Practice

Pharmacologic Treatment for Smoking Cessation

Approaches to Increase Access and Delivery of Evidence-Based Cessation Support in Cancer Care

RESEARCH CONSIDERATIONS AND THE FUTURE OF ADDRESSING TOBACCO USE ACROSS THE CONTINUUM OF CANCER CARE

3. Lifestyle Factors

INTRODUCTION

OBESITY

Obesity and Cancer Risk

Obesity and Cancer Outcomes

Obesity and Cancer Treatment–Related Complications

Weight Loss Interventions

PHYSICAL ACTIVITY

Physical Activity and Cancer Risk

Physical Activity and Cancer Outcomes

Sedentary Behavior

Exercise Interventions

NUTRITION

Nutrition and Cancer Risk

Nutrition and Cancer Outcomes

Dietary Interventions

MECHANISTIC DATA

LIFESTYLE GUIDELINES FOR CANCER PREVENTION AND CONTROL

CONCLUSION

4. Genetic Counseling & Testing

THE ONCOLOGY GENETIC TESTING LANDSCAPE

THE EVOLVING ROLE OF GENETIC COUNSELORS

RESPONSIBLY SCALING GENETIC SERVICES

PRACTICAL GUIDANCE FOR ORDERING AND INTERPRETING GENETIC TESTING

Identifying Candidates for Germline Genetic Testing

Genetic Test Selection

Test Result Interpretation and Management

ADDITIONAL ISSUES IN CANCER GENETIC COUNSELING

Potential Germline Implications of Tumor Genomic Profiling

Access and Equity

Genetic Testing in Children

Reproductive Issues

Psychosocial Issues

Insurance and Discrimination

CONCLUSION

PART II Cancer Therapeutics

5. Essentials of Radiation Therapy

INTRODUCTION

RADIATION PHYSICS

Physics of Photon Interactions

Photon Beam Generation and Treatment Delivery

Treatment Beam Characteristics and Dose Calculation Algorithms

TREATMENT PLANNING

OTHER TREATMENT MODALITIES

Clinical Application of Types of Radiation

TREATMENT INTENT

FRACTIONATION

ADVERSE EFFECTS

PRINCIPLES OF THE USE OF AGENTS THAT MODIFY THE RADIATION RESPONSE

6. Alkylating Agents

HISTORICAL PERSPECTIVES

CHEMISTRY

CLASSIFICATION

Alkyl Sulfonates

Aziridines

Triazines

Nitrogen Mustards

Nitrosoureas

CLINICAL PHARMACOKINETICS/PHARMACODYNAMICS

THERAPEUTIC USES

TOXICITIES

Nausea and Vomiting

Bone Marrow Toxicity

Renal and Bladder Toxicity

Interstitial Pneumonitis and Pulmonary Fibrosis

Gonadal Toxicity, Teratogenesis, and Carcinogenesis

Alopecia

Allergic Reactions

Immunosuppression

COMPLICATIONS WITH HIGH-DOSE ALKYLATING AGENT THERAPY

ALKYLATING AGENT–STEROID CONJUGATES

DRUG RESISTANCE AND MODULATION

FUTURE PERSPECTIVES

7. Platinum Analogs

INTRODUCTION

HISTORY

PLATINUM CHEMISTRY

PLATINUM COMPLEXES AFTER CISPLATIN

Carboplatin

Oxaliplatin

Other Approved Agents

Other Platinum Structures

MECHANISMS OF ACTION AND CELLULAR EFFECTS

Cell Entry

Aquation

DNA Lesions

DNA Damage Repair

DNA Damage Recognition

DNA Damage Response and Checkpoint Activation

Ribosome Biogenesis Stress

Signal Transduction

MECHANISMS OF RESISTANCE

Reduced Cell Entry

Increased Cell Efflux

Inactivation

DNA Damage Repair

DNA Damage Tolerance

COMBINATORIAL EFFORTS

Common Cytotoxic Regimens with Platinum Compounds

Platinum Compounds and DNA Damage Repair Inhibitors

Platinum Compounds and Immunotherapy

CLINICAL PHARMACOLOGY

Pharmacokinetics

Pharmacodynamics and Exposure Response Relationships

Pharmacogenomics

8. Antimetabolites

ANTIFOLATES

Mechanism of Action

Mechanisms of Resistance

Clinical Pharmacology

Toxicity

5-FLUOROPYRIMIDINES

Mechanism of Action

Mechanisms of Resistance

Clinical Pharmacology

Biomodulation of 5-FU

Toxicity

CAPECITABINE

Clinical Pharmacology

Toxicity

TRIFLURIDINE/TIPIRACIL

Clinical Pharmacology

Toxicity

CYTARABINE

Mechanism of Action

Mechanisms of Resistance

Clinical Pharmacology

Toxicity

GEMCITABINE

Mechanism of Action

Mechanisms of Resistance

Clinical Pharmacology

Toxicity

6-THIOPURINES

Mechanism of Action

Mechanisms of Resistance

Clinical Pharmacology

Toxicity

FLUDARABINE

Mechanism of Action

Mechanisms of Resistance

Clinical Pharmacology

Toxicity

CLADRIBINE

Mechanism of Action

Mechanisms of Resistance

Clinical Pharmacology

Toxicity

CLOFARABINE

Mechanism of Action

Mechanisms of Resistance

Clinical Pharmacology

Toxicity

NELARABINE

Mechanism of Action

Mechanisms of Resistance

Clinical Pharmacology

Toxicity

9. Topoisomerase-Interacting Agents

BIOCHEMICAL AND BIOLOGICAL FUNCTIONS OF TOPOISOMERASES

Classification of Topoisomerases

Biochemical Characteristics and Cleavage Complexes of the Different Topoisomerases

Differential Topoisomerization Mechanisms: Swiveling versus Strand Passage, DNA versus RNA Topoisomerases

TOPOISOMERASE INHIBITORS AS INTERFACIAL POISONS

Topoisomerase Inhibitors Act as Interfacial Inhibitors by Binding at the Topoisomerase–DNA Interface and Trapping Topoisomerase Cleavage Complexes

TOP1cc-targeted Drugs (Camptothecin and Indenoisoquinoline Derivatives) Kill Cancer Cells by Replication Collisions

Cytotoxic Mechanisms of TOP2cc-targeted Drugs (Intercalators and Demethylepipodophyllotoxins)

TOPOISOMERASE I INHIBITORS: CAMPTOTHECINS AND BEYOND

Irinotecan

Topotecan

Camptothecin Conjugates and Analogs

Noncamptothecin Topoisomerase I Inhibitors

TOPOISOMERASE II INHIBITORS: INTERCALATORS AND NONINTERCALATORS

Doxorubicin

Liposomal Doxorubicin

Daunorubicin

Epirubicin

Idarubicin

Cardiac Toxicity of Anthracyclines

Mitoxantrone

Dactinomycin

Epipodophyllotoxins

Etoposide

Teniposide

Therapy-related Secondary Acute Leukemia (t-AML)

TUMOR-TARGETED TOPOISOMERASE INHIBITORS

TOPOISOMERASE I INHIBITOR COMBINATIONS

DETERMINANTS OF RESPONSE TO TOPOISOMERASE INHIBITORS

10. Microtubule Inhibitors

MICROTUBULES

TAXANES

Mechanism of Action

Clinical Pharmacology

Drug Interactions

Toxicity

VINCA ALKALOIDS

Mechanism of Action

Clinical Pharmacology

Drug Interactions

Toxicity

MICROTUBULE ANTAGONISTS AND ADC PAYLOADS

Estramustine Phosphate

Epothilones

ANTIMICROTUBULE PAYLOADS OF ANTIBODY DRUG CONJUGATES

Maytansinoids and Auristatins: DM1, DM4, MMAE, MMAF

MITOTIC MOTOR PROTEIN INHIBITORS

MECHANISMS OF RESISTANCE TO MICROTUBULE INHIBITORS

11. Kinase Inhibitors as Anticancer Drugs

INTRODUCTION

VALIDATING MUTATED KINASES AS CANCER DRUG TARGETS—THE DEVELOPMENT OF IMATINIB FOR PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA AND GASTROINTESTINAL STROMAL TUMORS

THE DEVELOPMENT OF HER2-TARGETED THERAPIES IN BREAST AND OTHER CANCERS

THE DEVELOPMENT OF EGFR TYROSINE KINASE INHIBITORS IN LUNG CANCER

IDENTIFYING THERAPEUTIC TARGETS IN EGFR WILD-TYPE LUNG CANCERS

Anaplastic Lymphoma Kinase Fusions

ROS1 Fusions

RET Fusions

MET

BRAF–Mutant and other Molecularly Defined Lung Cancer Populations

TARGETING BRAF-MUTANT TUMORS WITH RAF AND MEK INHIBITORS

PI3 KINASE PATHWAY INHIBITORS

FGFR INHIBITORS: AN IMPORTANT CASE FOR ISOFORM SELECTIVITY

ONE TARGET OR SEVERAL: MULTITARGETED KINASE INHIBITOR THERAPY

CDK4/6 INHIBITORS

BRUTON TYROSINE KINASE INHIBITORS—AN EXAMPLE OF LINEAGE DEPENDENCE

TUMOR AGNOSTIC DRUG TARGETS—TRK INHIBITORS FOR NTRK FUSION POSITIVE CANCERS

FUTURE DIRECTIONS

12. Histone Deacetylase Inhibitors, Demethylating Agents, and Epigenetic Drugs

INTRODUCTION

THE CANCER EPIGENOME

DNA Methylation in Cancer

Histone Modifications in Cancer

DNA Methyltransferase Inhibitors

HISTONE DEACETYLASE INHIBITORS

OTHER EPIGENETIC DRUGS

13. Proteasome Inhibitors

BIOCHEMISTRY OF THE UBIQUITIN-PROTEASOME PATHWAY

PROTEASOME INHIBITORS

Chemical Classes of Proteasome Inhibitors in Clinical Development

Preclinical Activity of Proteasome Inhibitors

Pharmacokinetics and Pharmacodynamics of Proteasome Inhibitors in Animals

PROTEASOME INHIBITORS IN CANCER

Clinical Activity of Proteasome Inhibitors

Clinical Activity in Other Cancers

Mechanisms of Resistance

14. Poly(ADP-Ribose) Polymerase Inhibitors for Tumors with Defects in DNA Repair

INTRODUCTION

CELLULAR DNA REPAIR PATHWAYS

BRCA1 AND BRCA2 MUTATIONS AND DNA REPAIR

THE DEVELOPMENT OF PARP INHIBITORS

PARP-1 INHIBITION AS A SYNTHETIC LETHAL THERAPEUTIC STRATEGY FOR THE TREATMENT OF BRCA-DEFICIENT CANCERS

EARLY CLINICAL RESULTS TESTING SYNTHETIC LETHALITY OF PARP INHIBITORS AND BRCA MUTATION

CLINICAL STUDIES LEADING TO THE APPROVAL OF PARP INHIBITORS FOR THERAPEUTIC USE

THE USE OF PARP INHIBITORS IN NON-BRCA GERMLINE MUTANT CANCERS

MECHANISMS OF RESISTANCE TO PARP INHIBITORS

FUTURE PROSPECTS

DISCLOSURE

15. Miscellaneous Chemotherapeutic Agents

OMACETAXINE

HYDROXYUREA

MITOTANE

ARSENIC TRIOXIDE

BLEOMYCIN

MITOMYCIN-C

PROCARBAZINE

L-ASPARAGINASE

SIROLIMUS, TEMSIROLIMUS, EVEROLIMUS

THALIDOMIDE, LENALIDOMIDE, POMALIDOMIDE

MISCELLANEOUS AGENTS REPURPOSABLE FOR CANCER THERAPY

CARDIOVASCULAR DRUGS REPURPOSABLE FOR CANCER THERAPY

ANTIMICROBIAL DRUGS REPURPOSABLE FOR CANCER THERAPY

Antibiotics

Antivirals

Antifungals

Antihelmintics

ANTIDIABETIC DRUGS REPURPOSABLE FOR CANCER THERAPY

16. Hormonal Agents

INTRODUCTION

SELECTIVE ESTROGEN RECEPTOR MODULATORS

Tamoxifen

Endoxifen

Toremifene

Raloxifene

Lasofoxifene

Fulvestrant

Elacestrant

AROMATASE INHIBITORS

Letrozole and Anastrozole

Exemestane

RESISTANCE TO ENDOCRINE-TARGETED THERAPY IN BREAST CANCER

Combination and Developing Strategies to Overcome Endocrine Resistance in Breast Cancer

GONADOTROPIN-RELEASING HORMONE ANALOGS

Gonadotropin-Releasing Hormone Analogs

Gonadotropin-Releasing Hormone Antagonists

ANTIANDROGENS

Flutamide

Bicalutamide

Enzalutamide

Apalutamide

Darolutamide

Nilutamide

RESISTANCE TO ANDROGEN THERAPIES IN PROSTATE CANCER

Abiraterone Acetate

OTHER SEX STEROID THERAPIES

Fluoxymesterone

Estrogens: Diethylstilbestrol and Estradiol

Medroxyprogesterone and Megestrol

OTHER HORMONAL THERAPIES

Octreotide

17. Immunotherapy Agents: Monoclonal Antibodies

INTRODUCTION

IMMUNOGLOBULIN STRUCTURE

FACTORS REGULATING ANTIBODY-BASED TUMOR TARGETING

Antibody Size

Tumor Antigen Availability

Half-Life or Clearance Rate

UNCONJUGATED ANTIBODY MECHANISMS OF ACTION

Altering Signal Transduction

Complement-Dependent Cytotoxicity

Cell-Mediated Cytotoxicity

CONJUGATED ANTIBODIES

Radioimmunoconjugates

Antibody–Drug Conjugates

ANTIBODY MODIFICATIONS TO ENHANCE EFFICACY

Fc Mutagenesis

Glycosylation and Fucosylation

Bispecific

ANTIBODIES APPROVED FOR USE IN SOLID TUMORS

HER2 Targeting

EGFR Targeting

VEGF and VEGFR Targeting

GD2 Targeting

Other Targets

ANTIBODIES APPROVED FOR USE IN HEMATOLOGIC MALIGNANCIES

CD20 Targeting

CD19 Targeting

CD38 Targeting

CD22 Targeting

Other Targets

CONCLUSION

18. Immunotherapy Agents: Checkpoint Modulators

INTRODUCTION

PRECLINICAL WORK WITH CTLA-4

EARLY STUDIES WITH CTLA-4 ANTIBODIES IN METASTATIC CANCER

ADJUVANT TRIALS OF IPI

Immune-related Adverse Events

Immune-related Response Criteria

PRECLINICAL WORK WITH PD-1

EARLY STUDIES WITH PD-1 ANTIBODIES IN METASTATIC CANCER

ADJUVANT TRIALS OF NIVOLUMAB AND PEMBROLIZUMAB

NEOADJUVANT TRIALS OF NIVOLUMAB AND PEMBROLIZUMAB IN MELANOMA AND OTHER CANCERS

IMMUNE CHECKPOINT INHIBITOR COMBINATIONS

PD-1/PD-L1 Antagonists in Combination with Anti-CTLA-4

PD-1/PD-L1 Antagonists in Combination with Other Immune Modulators

PD/PD-L1 Antagonists in Combination with Chemotherapy

PD-1/PD-L1 Antagonists in Combination with VEGF Inhibitors

PD-PD-L1 Antagonists in Combination with Molecular Targeted Therapies

19. Immunotherapy Agents: Cellular Therapies

INTRODUCTION

TUMOR INFILTRATING LYMPHOCYTES (TIL)

Overview/Definition

Methods of Generation and Administration

Landmark Studies in Cutaneous Melanoma

Future Directions

CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS

Overview/Definition

Methods of Generation

Limitations/Challenges

Future Directions

T-CELL RECEPTOR ENGINEERED T CELLS (TCR)

OTHER POTENTIAL CELLULAR THERAPIES

NK Cells

Dendritic Cells

γδ T Cells

20. Immunotherapy Agents: Nonspecific Stimulators

ROLE IN THE TUMOR MICROENVIRONMENT

IL-2 VARIANT MOLECULES—IMPROVING THE SAFETY AND EFFICACY OF HIGH-DOSE IL-2

ANTIBODY-CYTOKINE FUSION (IMMUNOCYTOKINES)

ONCOLYTIC VIRUSES

TALIMOGENE LAHERPAREPVEC

OTHER ONCOLYTIC VIRUSES

CLINICAL APPLICATION

TOLL-LIKE RECEPTOR AGONISTS

STING AGONISTS

T-CELL ACTIVATORS

4-1BB (CD137)

GITR (GLUCOCORTICOID-INDUCED TNF-R-RELATED PROTEIN)

ICOS (INDUCIBLE T-CELL COSTIMULATOR)

OX40

CD40

CYTOKINES OTHER THAN IL-2

21. Allogeneic Stem Cell Transplantation

INTRODUCTION

CONDITIONING REGIMENS

Myeloablative Conditioning

Reduced-Intensity Conditioning

Nonmyeloablative Conditioning

Radioimmunotherapy

HEMATOPOIETIC STEM AND PROGENITOR CELL SOURCES

HLA-Matched Related Donors

Unrelated Donors

Partially Matched Related Donors

Umbilical Cord Donors

IMMUNOBIOLOGY OF TRANSPLANTATION

Graft-versus-Host Disease

Graft-versus-Leukemia

COMPLICATIONS OF ALLOGENEIC STEM CELL TRANSPLANTATION AND THEIR MANAGEMENT

Acute Graft-versus-Host Disease

Chronic Graft-versus-Host Disease

Opportunistic Infections

GRAFT FAILURE

Organ-Specific Complications

MAJOR DISEASE INDICATIONS FOR ALLOGENEIC STEM CELL TRANSPLANTATION

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Myelodysplasia

Transplantation for Other Malignancies

PREVENTION AND TREATMENT OF POSTTRANSPLANT RELAPSE

FUTURE DIRECTIONS

PART III Practice of Oncology

22. Design and Analysis of Clinical Trials

INTRODUCTION

PHASE I CLINICAL TRIALS

Accelerated Titration Designs

Continual Reassessment Methods

Other Methods

PHASE II CLINICAL TRIALS

Patient Selection

Single-Arm Phase II Trials

DESIGN OF PHASE III CLINICAL TRIALS

End Points

Patient Eligibility

Randomization

Stratification

Sample Size

FACTORIAL DESIGNS

Noninferiority Trials

Bayesian Methods

ANALYSIS OF PHASE III CLINICAL TRIALS

Intention-to-Treat Analysis

Interim Analyses

Significance Levels, Hypothesis Tests, and Confidence Intervals

Calculation of Survival Curves

Multiple Comparisons

REPORTING RESULTS OF CLINICAL TRIALS

FALSE-POSITIVE REPORTS IN THE LITERATURE

META-ANALYSIS

People also search for DeVita Hellman and Rosenberg s Cancer Principles and Practice of Oncology 12th Edition:

    
cancer principles and practice of oncology 12th edition pdf
    
devita cancer principles and practice of oncology pdf
    
cancer principles and practice of oncology pdf
    
cancer principles and practice of oncology 11th edition pdf
    
cancer principles and practice of oncology (12th edition)

Tags: Vincent T Devita Jr, Theodore S Lawrence, Steven A Rosenberg, Cancer Principles, Oncology